The role of circulating free DNA in the management of NSCLC

2018 ◽  
Vol 19 (1) ◽  
pp. 19-28 ◽  
Author(s):  
Riziero Esposito Abate ◽  
Raffaella Pasquale ◽  
Francesca Fenizia ◽  
Anna Maria Rachiglio ◽  
Cristin Roma ◽  
...  
Author(s):  
M. Del Re ◽  
V. Conteduca ◽  
S. Crucitta ◽  
G. Gurioli ◽  
C. Casadei ◽  
...  

Abstract Background Androgen receptor (AR) signaling inhibitors represent the standard treatment in metastatic castration resistance prostate cancer (mCRPC) patients. However, some patients display a primary resistance, and several studies investigated the role of the AR as a predictive biomarker of response to treatment. This study is aimed to evaluate the role of AR in liquid biopsy to predict clinical outcome to AR signaling inhibitors in mCRPC patients. Methods Six milliliters of plasma samples were collected before first-line treatment with abiraterone or enzalutamide. Circulating free DNA (cfDNA) and exosome-RNA were isolated for analysis of AR gain and AR splice variant 7 (AR-V7), respectively, by digital droplet PCR. Results Eighty-four mCRPC patients received abiraterone (n = 40) or enzalutamide (n = 44) as first-line therapy. Twelve patients (14.3%) presented AR gain and 30 (35.7%) AR-V7+ at baseline. Median progression-free survival (PFS) and overall survival (OS) were significantly longer in AR-V7− vs AR-V7+ patients (24.3 vs 5.4 months, p < 0.0001; not reached vs 16.2 months, p = 0.0001, respectively). Patients carrying the AR gain had a median PFS of 4.8 vs 24.3 months for AR normal patients (p < 0.0001). Median OS was significantly longer in AR normal vs patients with AR gain (not reached vs 8.17 months, p < 0.0001). A significant correlation between AR-V7 and AR gain was observed (r = 0.28; p = 0.01). The AR gain/AR-V7 combined analysis confirmed a strong predictive effect for biomarkers combination vs patients without any AR aberration (PFS 3.8 vs 28 month, respectively; OS 6.1 vs not reached, respectively; p < 0.0001). Conclusions The present study demonstrates that cfDNA and exosome-RNA are both a reliable source of AR variants and their combined detection in liquid biopsy predicts resistance to AR signaling inhibitors.


2015 ◽  
Vol 2015 ◽  
pp. 1-9 ◽  
Author(s):  
Shigeto Hamaguchi ◽  
Yukihiro Akeda ◽  
Norihisa Yamamoto ◽  
Masafumi Seki ◽  
Kouji Yamamoto ◽  
...  

Recently, it has been reported that circulating free DNA (cf-DNA) in the blood is increased in various infectious diseases, including sepsis. Moreover, a relationship between cf-DNA and neutrophil extracellular traps (NETs) has been suggested. However, it is still unclear what the source and physiological role of cf-DNA in sepsis are. In this study, we examined the source of cf-DNA by detecting citrullinated histone H3, a characteristic feature of NET formation, in cecal ligation and puncture- (CLP-)operated mice. In addition, neutrophil depletion using anti-Ly6G antibodies was performed to assess the association between neutrophils and cf-DNA. Increased cf-DNA levels were observed only in CLP mice and not in the control groups; the qPCR findings revealed that the cf-DNA was mainly host-derived, even in bacteremic conditions. Citrullinated histone H3 was not increased in the neutrophils upon CLP, and the depletion of neutrophils showed limited effects on decreasing the amount of cf-DNA. Taken together, these results suggested that elevated cf-DNA levels during early-phase sepsis may represent a candidate biomarker for the severity of sepsis and that, contrary to previous findings, cf-DNA is not derived from neutrophils or NETs.


2016 ◽  
Vol 8 (12) ◽  
pp. 810 ◽  
Author(s):  
Alexios Matikas ◽  
Alexandra Voutsina ◽  
Maria Trypaki ◽  
Vassilis Georgoulias

2010 ◽  
Vol 138 (5) ◽  
pp. S-67
Author(s):  
Béla Molnár ◽  
Kinga Tóth ◽  
Sándor Spisák ◽  
Orsolya Galamb ◽  
Ottó Jász ◽  
...  

Author(s):  
Lorenzo Gerratana ◽  
Andrew A. Davis ◽  
Ami N. Shah ◽  
Chenyu Lin ◽  
Carla Corvaja ◽  
...  
Keyword(s):  

2021 ◽  
Vol 17 (1) ◽  
pp. 12-17
Author(s):  
Yang Zhou ◽  
Dongrui Cheng ◽  
Tingya Jiang

Sign in / Sign up

Export Citation Format

Share Document